CY1117307T1 - Μεταφορα γονιδιου εντος επιθηλιακου βλαστοκυτταρου αεροδου με χρηση φακοϊικου φορεα ψευδοτυποποιημενου με πρωτεϊνη αιχμης rna ιου - Google Patents

Μεταφορα γονιδιου εντος επιθηλιακου βλαστοκυτταρου αεροδου με χρηση φακοϊικου φορεα ψευδοτυποποιημενου με πρωτεϊνη αιχμης rna ιου

Info

Publication number
CY1117307T1
CY1117307T1 CY20161100081T CY161100081T CY1117307T1 CY 1117307 T1 CY1117307 T1 CY 1117307T1 CY 20161100081 T CY20161100081 T CY 20161100081T CY 161100081 T CY161100081 T CY 161100081T CY 1117307 T1 CY1117307 T1 CY 1117307T1
Authority
CY
Cyprus
Prior art keywords
protein
gene
cyclopees
blast
length
Prior art date
Application number
CY20161100081T
Other languages
English (en)
Inventor
Katsuyuki Mitomo
Makoto Inoue
Hitoshi Iwasaki
Mamoru Hasegawa
Eric W Alton
Uta Griesenbach
Original Assignee
Id Pharma Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Pharma Co., Ltd filed Critical Id Pharma Co., Ltd
Publication of CY1117307T1 publication Critical patent/CY1117307T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/609—Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Ένα γονίδιο μεταφέρεται επιτυχώς εντός επιθηλιακών βλαστοκυττάρων αεροδού με χρήση φορέα ιού ανοσοανεπάρκειας πιθηκοειδούς που έχει ψευδοτυποποιηθεί με γλυκοπρωτεΐνες F και ΗΝ θύλακα του ιού Sendai. Αυτή η μεταφορά γονιδίου εντός επιθηλιακών βλαστοκυττάρων αεροδού με την χρήση του φορέα όπως περιγράφεται ανωτέρω είναι χρήσιμη σε γονιδιακή θεραπεία για κληρονομική αναπνευστική νόσο, όπως κυστική ίνωση. Περαιτέρω, καθίσταται δυνατόν να επιλεγεί αναπνευστικό όργανο όπως ο πνεύμονας, ως ιστός που είναι ικανός παραγωγής και παροχής μιας πρωτεΐνης ελαττωματικής σε κληρονομική νόσο.
CY20161100081T 2005-10-28 2016-01-28 Μεταφορα γονιδιου εντος επιθηλιακου βλαστοκυτταρου αεροδου με χρηση φακοϊικου φορεα ψευδοτυποποιημενου με πρωτεϊνη αιχμης rna ιου CY1117307T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005313971 2005-10-28
EP06822478.1A EP1950307B8 (en) 2005-10-28 2006-10-27 Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus spike protein

Publications (1)

Publication Number Publication Date
CY1117307T1 true CY1117307T1 (el) 2017-04-26

Family

ID=37967860

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100081T CY1117307T1 (el) 2005-10-28 2016-01-28 Μεταφορα γονιδιου εντος επιθηλιακου βλαστοκυτταρου αεροδου με χρηση φακοϊικου φορεα ψευδοτυποποιημενου με πρωτεϊνη αιχμης rna ιου

Country Status (13)

Country Link
US (4) US20090162320A1 (el)
EP (2) EP2993235B1 (el)
JP (3) JPWO2007049752A1 (el)
KR (1) KR20080068098A (el)
CN (1) CN101351557A (el)
CA (1) CA2627485C (el)
CY (1) CY1117307T1 (el)
DK (1) DK1950307T3 (el)
ES (2) ES2561060T3 (el)
HU (1) HUE028512T2 (el)
PT (1) PT1950307E (el)
SI (1) SI1950307T1 (el)
WO (1) WO2007049752A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
KR101753069B1 (ko) 2015-07-17 2017-07-04 서울대학교병원 헤마글루티닌-뉴라미니다아제와 f 단백질을 과발현하는 중간엽줄기세포 및 그 용도
CN111225682A (zh) * 2017-10-20 2020-06-02 吉尼松公司 合胞素用于将药物和基因靶向递送至肺组织的用途
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
CN111088408A (zh) * 2020-03-20 2020-05-01 广州凯普医药科技有限公司 一种新冠病毒、甲乙流感及呼吸道合胞病毒检测试剂盒
CN112011521A (zh) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 一种重组新城疫病毒载体新型冠状病毒疫苗候选株及其构建方法和应用
WO2022055894A1 (en) * 2020-09-08 2022-03-17 The Regents Of The University Of California Sars-cov-2 spike glycoprotein for virus generation and pseudotyping
WO2023199049A1 (en) * 2022-04-11 2023-10-19 Ip2Ipo Innovations Limited Combination treatment

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162215A (en) * 1988-09-22 1992-11-10 Amgen Inc. Method of gene transfer into chickens and other avian species
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5576201A (en) * 1994-01-14 1996-11-19 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
KR100754091B1 (ko) * 1995-10-31 2007-08-31 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 ｒｎａ 바이러스 벡터
JP3992200B2 (ja) 1995-11-01 2007-10-17 株式会社ディナベック研究所 組換え体センダイウイルスを利用した膜融合性リポソーム
CA2236378C (en) * 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
DE69738737D1 (de) 1996-12-16 2008-07-10 Eisai R&D Man Co Ltd Verfahren zur herstellung von retroviralen vektoren für die gentherapie
AU9399498A (en) 1997-09-18 1999-04-05 Trustees Of The University Of Pennsylvania, The Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
DE19851282A1 (de) 1998-11-06 2000-05-11 Schweiz Serum & Impfinst Zusammensetzung einer pharmazeutisch wirksamen Substanz, appliziert in einem spezifischen Delivery-System zur Prävention und Behandlung von Infektions-Krankheiten
DE19909769A1 (de) * 1999-03-05 2000-09-07 Bundesrepublik Deutschland Let Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
KR20070058607A (ko) 1999-05-18 2007-06-08 가부시키가이샤 디나벡크 겐큐쇼 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터
WO2001018223A1 (fr) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramoxyvirus possedant une sequence d'initiation de transcription modifiee
ES2280254T3 (es) * 1999-11-02 2007-09-16 Dnavec Research Inc. Vector de virus sendai recombinante para introducir genes exogenos en el epitelio de las vias respiratorias.
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
CN1418252A (zh) * 2000-01-19 2003-05-14 株式会社载体研究所 副粘病毒属载体在血管内基因转移中的用途
EP1270016A4 (en) * 2000-03-30 2005-10-19 Dnavec Research Inc VACCINE AGAINST AIDS VIRUS CONTAINING A VECTOR OF SENDAI VIRUS
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CN100531802C (zh) * 2000-06-01 2009-08-26 株式会社载体研究所 含有血凝素活性膜蛋白质的假型逆转录病毒载体
JP5014535B2 (ja) 2000-06-15 2012-08-29 田辺三菱製薬株式会社 カニクイザル由来胚性幹細胞
US20030170897A1 (en) * 2000-06-27 2003-09-11 Enyu Imai Virus vector for transferring gene into renal cells
EP1333088A4 (en) * 2000-10-06 2004-11-24 Dnavec Research Inc PARAMYXOVIRUS VECTOR FOR THE INTRODUCTION OF FOREIGN GENES IN SKELETAL MUSCLE
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
WO2002042481A1 (fr) * 2000-11-27 2002-05-30 Dnavec Research Inc. Vecteur paramyxovirus codant pour un gene d'angiogenese et son utilisation
CA2449589A1 (en) 2001-06-08 2002-12-19 Dnavec Research Inc. Gene transfer into primate embryonic stem cells using vsv-g pseudotyped simian immunodeficiency virus vector
GB0202569D0 (en) 2002-02-04 2002-03-20 Oxford Biomedica Ltd Delivery means
US7402427B2 (en) 2002-04-30 2008-07-22 Dnavec Research Inc. Vectors with modified protease-dependent tropism
WO2003092582A2 (en) * 2002-04-30 2003-11-13 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor
EP1504766A4 (en) 2002-04-30 2006-11-02 Dnavec Research Inc MEDICAMENT OR GENE SUPPORT COMPOSITION WITH HEMAGGLUTININ ACTIVITY
CA2488270A1 (en) 2002-06-03 2003-12-11 Dnavec Research Inc. Paramyxoviral vectors encoding antibodies, and uses thereof
EP1548101A4 (en) 2002-09-04 2006-05-10 Dnavec Research Inc METHOD FOR PRODUCING A VIRAL VECTOR CONTAINING A MEMBRANE PROTEIN BINDING WITH THE NEURAMINIDASE FROM GRAM-POSITIVE BACTERIA TO SIALIC ACID AS AN INTEGRAL PART OF THE ENVELOPE
JPWO2004038029A1 (ja) 2002-10-24 2006-02-23 株式会社ディナベック研究所 Ｔ細胞に遺伝子を導入する方法
US20050113298A1 (en) * 2003-09-15 2005-05-26 The Brigham And Women's Hospital, Inc. Receptor binding peptides derived from the SARS S protein
US20050100890A1 (en) * 2003-10-15 2005-05-12 Davidson Beverly L. Methods for producing and using in vivo pseudotyped retroviruses
WO2005087936A1 (ja) 2004-03-16 2005-09-22 Dnavec Research Inc. 胚性幹細胞に遺伝子を導入する方法

Also Published As

Publication number Publication date
US20160281109A1 (en) 2016-09-29
EP1950307B8 (en) 2016-02-24
EP2993235B1 (en) 2019-02-13
EP1950307A1 (en) 2008-07-30
EP1950307A4 (en) 2010-09-08
US20150174198A1 (en) 2015-06-25
JPWO2007049752A1 (ja) 2009-04-30
CN101351557A (zh) 2009-01-21
KR20080068098A (ko) 2008-07-22
WO2007049752A1 (ja) 2007-05-03
ES2561060T3 (es) 2016-02-24
US20190225986A1 (en) 2019-07-25
SI1950307T1 (sl) 2016-02-29
HUE028512T2 (en) 2016-12-28
DK1950307T3 (en) 2016-02-15
JP5776662B2 (ja) 2015-09-09
CA2627485C (en) 2017-02-21
JP2015126753A (ja) 2015-07-09
EP2993235A1 (en) 2016-03-09
US10017784B2 (en) 2018-07-10
EP1950307B1 (en) 2015-12-23
ES2726176T3 (es) 2019-10-02
PT1950307E (pt) 2016-02-29
JP2013055941A (ja) 2013-03-28
US20090162320A1 (en) 2009-06-25
CA2627485A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
CY1117307T1 (el) Μεταφορα γονιδιου εντος επιθηλιακου βλαστοκυτταρου αεροδου με χρηση φακοϊικου φορεα ψευδοτυποποιημενου με πρωτεϊνη αιχμης rna ιου
ES2667644T3 (es) UTR que aumentan la eficacia de la traducción de las moléculas de ARN
CY1115246T1 (el) Τροποποιησεις toy rna, οι οποιες οδηγουν σε αυξημενη σταθεροτητα μεταγραφηματων και αποτελεσματικοτητα μεταφρασης
CY1111494T1 (el) ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ
CY1110272T1 (el) Αθανατοποιημενες κυτταρικες σειρες πτηνων για παραγωγη ιου
NO20071953L (no) RNAi modulering av RSV, PIV og andre respiratoriske viruser og anvendelse derav
CY1116279T1 (el) Η χρηση των ανθρωπινων κυτταρων προελευσης μυελογενους λευχαιμιας για την εκφραση αντισωματων
BRPI0411475A (pt) adições de código genético de aminoácido reativo não natural
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
CL2008003794A1 (es) Virus de la estomatitis vesicular geneticamente modificado (vsv) que comprende por lo menos una mutacion de aminoacido en una region de alguna de las proteinas m, g y l del virus; metodo para producirlo; composicion inmunogenica que lo comprende; metodo para adaptar un virus en un cultivo celular.
ATE362989T1 (de) Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
EP1179594A4 (en) RIBONUCLEOPROTEIN FROM PARAMYXOVIRUS
WO2003092582A3 (en) Chimeric ebola virus envelopes and uses therefor
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
CY1105979T1 (el) Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων
PT1005538E (pt) Proteinas do canal de potassio para serem utilizadas na terapia de genes para melhoria da disfuncao erectil
ATE443158T1 (de) Vektorvermittelte organellentransfektion
MY162658A (en) Genes encoding major capsid protein l1 of human papilloma virus and use of the same
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
ATE338826T1 (de) Rekombinante virale vektoren zur tetracyclinregulierbaren genexpression
AR069884A1 (es) Metodos para empacar vectores de virus de estomatitis vesicular de propagacion defectuosa
ATE453708T1 (de) Impfstoff gegen west nile virus
WO2007045062A8 (en) Plasmid expression vectors for expression of recombinant rotavirus and astrovirus proteins or epitopes.